3 not yet recruiting, 3 recruiting, 3 unknown, 2 completed. 12 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Not yet recruiting 3, Recruiting 3, Unknown 3, Completed 2, Active not recruiting 1 |
| Phase 1 | 3 | Recruiting 2, Unknown 1 |
Follow Ovarian Clear Cell Carcinoma: new trials by email Literature Review of Ovarian Clear Cell Carcinoma trials Research Report on Ovarian Clear Cell Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase II Investigator-initiated Trial of Sacituzumab Tirumotecan Plus Pembrolizumab in Patients With Recurrent ovarIan Clear Cell Carcinoma Previously Treated With Platinum-based Chemotherapy（NCCH2407/MK014） Sacituzumab tirumotecan, Pembrolizumab - Ovarian Clear Cell Carcinoma | Phase 2 | Not yet recruiting | National Cancer Center, Japan | 32 | 2027-02-01 | 2026-11-03 |
| TR115 in ARID1A-Mutated Advanced Solid Tumors TR115 - Ovarian Clear Cell Carcinoma, Endometrial Cancer | Phase 2 | Not yet recruiting | Tarapeutics Science Inc. | 50 | 2026-09-20 | 2026-08-28 |
| Sacituzumab Tirumotecan +/- Pembrolizumab in I/O Exposed Metastatic or Recurrent Ovarian Clear Cell Cancer Sacituzumab tirumotecan, Pembrolizumab - Ovarian Clear Cell Carcinoma, Metastatic Ovarian Cancer | Phase 2 | Recruiting | Tufts Medical Center | 50 | 2026-09-01 | 2026-09-16 |
| Liposomal Irinotecan Combined With Sintilimab and Anlotinib in the Treatment of Recurrent or Persistent Ovarian Clear Cell Carcinoma Treatment - Ovarian Cancer, Ovarian Clear Cell Carcinoma | Phase 2 | Not yet recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 36 | 2026-01-01 | 2025-11-20 |
| Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100 Dostarlimab, LB-100 - Ovarian Clear Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 21 | 2023-11-10 | 2026-06-23 |
| Zimberelimab Plus Metformin for Recurrent Ovarian Clear Cell Carcinoma Zimberelimab, Metformin Hydrochloride - Ovarian Clear Cell Carcinoma | Phase 1 / Phase 2 | Unknown | Fudan University | 20 | 2023-03-01 | 2023-03-08 |
| Pembrolizumab and Lenvatinib in Clear Cell Ovarian Cancer Lenvatinib, Pembrolizumab - Ovarian Clear Cell Carcinoma, Gynecologic Cancer | Phase 2 | Active not recruiting | Elizabeth K. Lee MD | 30 | 2022-09-23 | 2026-11-04 |
| Sintilimab Plus Bevacizumab in Recurrent/Persistent Ovarian Clear Cell Carcinoma Sintilimab, Bevacizumab Biosimilar IBI305 - Ovarian Clear Cell Carcinoma | Phase 2 | Completed | Tongji Hospital | 38 | 2021-04-07 | 2024-08-13 |
| A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas Tulmimetostat, Enzalutamide - Advanced Solid Tumor, Diffuse Large B Cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Novartis Pharmaceuticals | 300 | 2019-09-18 | 2026-08-19 |
| A Multicentre Phase II Trial of Durvalumab Versus Physician's Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinomas durvalumab, standard chemotherapy - Ovarian Clear Cell Carcinoma | Phase 2 | Unknown | National University Hospital, Singapore | 46 | 2017-10-09 | 2018-05-18 |
| Study Of Nintedanib Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium Nintedanib, Paclitaxel, Pegylated Liposomal Doxorubicin (PLD) - Ovarian Clear Cell Carcinoma, Endometrial Clear Cell Carcinoma | Phase 2 | Unknown | NHS Greater Glasgow and Clyde | 120 | 2015-04-01 | 2016-08-15 |
| A Study of ENMD-2076 in Ovarian Clear Cell Cancers ENMD-2076 - Ovarian Clear Cell Carcinoma | Phase 2 | Completed | University Health Network, Toronto | 40 | 2013-09-01 | 2019-12-13 |
Endometrial Neoplasms (2) · Neoplasms (2) · Ovarian Neoplasms (2) · Adenocarcinoma, Clear Cell (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Lymphatic Diseases (1) · Lymphoma (1) · Lymphoma, B-Cell (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Non-Hodgkin (1) · Lymphoma, T-Cell (1) · Lymphoproliferative Disorders (1) · Mesothelioma, Malignant (1) · Neoplasms by Histologic Type (1)
Female Urogenital Diseases (4) · Female Urogenital Diseases and Pregnancy Complications (4) · Genital Diseases (4) · Genital Diseases, Female (4) · Genital Neoplasms, Female (4) · Urogenital Diseases (4) · Urogenital Neoplasms (4) · Neoplasms (3) · Neoplasms by Site (3) · Adnexal Diseases (2) · Endocrine Gland Neoplasms (2) · Endocrine System Diseases (2) · Gonadal Disorders (2) · Male Urogenital Diseases (2) · Neoplasms, Glandular and Epithelial (2)
pembrolizumab (3) · Carboplatin (1) · Doxorubicin (1) · ENMD 2076 (1) · LB100 (1) · Metformin (1) · Paclitaxel (1) · Therapeutics (1) · Topotecan (1) · dostarlimab (1) · durvalumab (1) · enzalutamide (1) · lenvatinib (1) · liposomal doxorubicin (1) · nintedanib (1)
Elizabeth K. Lee MD (1) · Fudan University (1) · M.D. Anderson Cancer Center (1) · NHS Greater Glasgow and Clyde (1) · National Cancer Center, Japan (1) · National University Hospital, Singapore (1) · Novartis Pharmaceuticals (1) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (1) · Tarapeutics Science Inc. (1) · Tongji Hospital (1) · Tufts Medical Center (1) · University Health Network, Toronto (1)
United States (4) · China (2) · United Kingdom (2) · Canada (1) · France (1) · Italy (1) · Japan (1) · Poland (1) · Singapore (1) · South Korea (1) · Spain (1)
Amir Jazaeri, M D (1) · Amit Oza, M.D. (1) · David SP Tan (1) · Elizabeth K Lee, MD (1) · Huaiwu Lu (1) · Libing Xiang (1) · Rosalind Glasspool (1)
PMID 32591370, PMID 35613822, PMID 37185961, PMID 38932511, PMID 39276785
2023 (1)